News Rumours of $1.65bn GSK bid for respiratory partners Vectura GlaxoSmithKline could be poised to acquire its respiratory partner, UK biotech Vectura, for $1.65bn.
Views & Analysis Inhalation technology: the future of effective respiratory t... Simon Moore discusses non-clinical development channels: technical strategies, formulations and devices.
News AZ's asthma drug Fasenra approved in EU A further 3,400 children are eligible for treatment with Orkambi
News Sunovion's COPD nebuliser approved in US Device aims to help patients get a full dose of medication
News GSK looks to expand reach of key COPD drug Trelegy GlaxoSmithKline and partner Innoviva are seeking an expansion to the US label of their Trelegy Ellipta lung drug.
News Immunovant's thyroid eye disease drug flunks pivotal trials Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
